RUNX1 and myeloid neoplasm: To date, following treatment of myeloid malignancies with inv(3)/t(3;3) or EVI1 overexpression with targeted therapies, including DNA hypomethylating drugs, venetoclax or glasdegib, or with FLT3 TKI or IDH1/2 inhibitors, clinical outcome data are unavailable80.